Drug intelligence / Profile preview

YJ001

Development stage: Phase 1
Lead developer: Zhejiang Hanmai Pharmaceutical Technology
Modality: Small Molecules, Transdermal Patches → Device-based Delivery → Drug Delivery Systems, Hydrogel Systems → Drug Delivery Systems
Administration: Topical

Overview

YJ001 is an investigational drug developed as a topical spray for the treatment of diabetic neuropathic pain (DNP), also referred to as diabetic peripheral neuropathic pain (DPNP). It is designed to be applied locally to the skin, particularly on both feet, with the aim of reducing systemic exposure and minimizing adverse reactions. Clinical studies have shown that YJ001 significantly reduces pain and improves sleep quality in patients with DNP compared to placebo, while demonstrating a favorable safety profile and low systemic absorption. The precise mechanism of action remains unknown. The drug has reached Phase 2 clinical trials in China for DNP.

Other names: YJ-001YJ001YJ 001

Beyond the preview

Go deeper on YJ001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on YJ001.

Explore the full profile